
It's time to wrap up our list of 10 stocks under $10. The list was culled from a large grouping of momentum names that have outperformed on a relative-strength basis during the short and intermediate term. The selection was filtered to eliminate any stocks trading above the $10 region, naturally, and then adjusted for other fundamental, technical, and sentiment factors. I hope you've had fun learning about some potential bargains for your portfolio and hearing the stories behind some equities that you've likely not come across in your daily investing research.
The last entry (and these have been in no particular order, by the way) is
Allos Therapeutics (NASDAQ:
ALTH). The pharmaceutical company is hard at work on technology that improves existing cancer medications. According to
Hoovers Online, ALTH's current lead drug candidate -- PDX -- is in trials to combat T-cell lymphoma. Some of the firm's other proposed treatments work to fight solid tumors and lymphoma.